Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2013
20 Mars 2013 - 7:54PM
Marketwired
Pharma-Bio Serv. (OTCQB: PBSV), a global compliance and validation
services consulting solutions provider, announced net revenues of
$7.6 million for the quarter ended January 31, 2013, an increase of
approximately $1.3 million, or 20%, compared to the same period in
2012.
The Company reported net income for the quarter ended January
31, 2013 of approximately $1 million, a slight decrease of $0.1
million compared to the same period in 2012.
During the quarter ended January 31, 2013, business development
and operations support expenses in the Puerto Rico and United
States markets were increased to follow the consulting business
favorable revenue trend. In addition, during the quarter ended
January 31, 2013, the Company made business development investments
in Spain to diversify its European division market.
"We are very pleased with our overall performance, particularly
in our U.S. Consulting Services," said Nélida Plaza, Acting Chief
Executive Officer, Acting President, Secretary and President of
Puerto Rico Operations.
About Pharma-Bio Serv Inc.
Pharma-Bio Serv is a global compliance and validation services
consulting solutions provider, headquartered in Puerto Rico, with
operations in the U.S, Ireland and Spain. Pharma-Bio Serv's core
business is FDA and international agencies regulatory compliance
related services with integrated portfolio services including
microbiological and chemical testing services for clients in the
Pharmaceutical, Biotechnology, Chemical, Medical Device, Cosmetic,
Food and Allied Products industries, at its laboratory testing
facility in Puerto Rico. Services also include "Integratek," an
information technology consulting practice and "Pharma Serv
Academy" a division that provides technical and regulatory
standards seminars/training conducted by industry experts. The
Company's global team includes more than 275 leading engineering
and life science professionals, quality assurance managers and
directors.
Forward-Looking Statements
This news release contains "forward-looking statements" within
the meaning of the U.S. federal securities laws, which statements
may include information regarding the plans, intentions,
expectations, future financial performance, or future operating
performance of Pharma-Bio Serv. Forward-looking statements are
based on the expectations, estimates, or projections of management
as of the date of this news release. Although Pharma-Bio Serv's
management believes these expectations, estimates, or projections
to be reasonable as of the date of this news release,
forward-looking statements are inherently subject to significant
business risks, economic and competitive uncertainties, or other
contingencies which could cause its actual results or performance
to differ materially from what may be expressed or implied in the
forward-looking statements. Important factors that could cause
Pharma-Bio Serv's actual results or performance to differ
materially from the forward-looking statements include those set
forth in the "Risk Factors" section of Pharma-Bio Serv's Annual
Report on Form 10-K for the year ended October 31, 2012 and in its
other filings with the Securities and Exchange Commission, which
filings are available on www.sec.gov. Pharma-Bio Serv disclaims any
intention or obligation to update or revise any forward-looking
statements to reflect subsequent events and circumstances, except
to the extent required by applicable law.
Investor Relations Contact: Scott Gordon CorProminence LLC
scottg@corprominence.com
Pharma Bio Serv (QB) (USOTC:PBSV)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Pharma Bio Serv (QB) (USOTC:PBSV)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024